Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on May 12, 2009
JNCI Journal of the National Cancer Institute 2009 101(10):702-704; doi:10.1093/jnci/djp136
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/10/702    most recent
djp136v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Friedrich, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedrich, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2009.

NEWS

Childhood ALL Researchers Focus on High-Risk Patients

Mary Jane Friedrich

The first 150 words of the full text of this article appear below.

Pediatric acute lymphoblastic leukemia (ALL) is one of the great success stories in oncology, with overall survival rising from less than 5% 50 years ago to more than 80% today. But there is one group of patients for whom outcomes have not improved: children who relapse.

Illustrating the differences in outcome are two recent analyses by the Children's Oncology Group (COG), said Stephen Hunger, M.D., of the University of Colorado Denver School of Medicine, who chairs COG's ALL committee.

On the positive side, in a review of 21,644 pediatric patients enrolled in COG ALL studies between 1990 and 2005, Hunger and his colleagues found that the 5-year overall survival rate improved substantially from 83.6% between 1990 and 1994 to 90.3% between 2000 and 2005. The flip side to this success story is an analysis of 1,961 patients who relapsed after treatment on COG frontline trials between 1988 and 2002. During . . . [Full Text of this Article]

Scanning the Genome

Clinical Relevance

Examining Host Factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?